Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs

Seeking Alpha total revenues. Given Teva's experience marketing generic products, Simlandi is expected to have some impact on their bottom line, though its potential is undeniably limited due to the presence of several other Humira biosimilars on the market. Teva highlighted data on their long-acting, subcutaneous formulation of a popular anti-psychotic drug, risperidone, Uzedy. Uzedy can be given every one or two months to treat schizophrenia. The pharmacokinetic data remained consistent when patients swit ...